NASDAQ:ATNX - Athenex Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $12.39 -0.16 (-1.27 %) (As of 12/14/2018 10:55 AM ET)Previous Close$12.55Today's Range$12.37 - $12.5752-Week Range$9.83 - $20.90Volume52,605 shsAverage Volume376,800 shsMarket Capitalization$899.05 millionP/E Ratio-5.34Dividend YieldN/ABeta0.38 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is under development to treat lung, ovarian, and cervical cancer; and oral eribulin co-administered with HM30181A that is under pre-clinical development to treat certain patients with breast cancer and advanced liposarcom. In addition, the company offers Src Kinase product candidates comprising KX-01, a compound, which is in Phase 3 study for the treatment of actinic keratosis; and KX-02 that is Phase I clinical trial for solid tumor patients. Further, it is developing intranasal formulations of granisetron, a 5-hydroxytryptamine 3 receptor antagonist to prevent chemotherapy-induced nausea and vomiting; and dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. has a strategic partnership with Hanmi Pharmaceuticals to develop their Orascovery and KX-01 programs. The company was founded in 2003 and is headquartered in Buffalo, New York. Receive ATNX News and Ratings via Email Sign-up to receive the latest news and ratings for ATNX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATNX Previous Symbol CUSIPN/A Webwww.athenex.com Phone716-427-2950 Debt Debt-to-Equity Ratio0.30 Current Ratio4.46 Quick Ratio3.86 Price-To-Earnings Trailing P/E Ratio-5.34 Forward P/E Ratio-6.26 P/E GrowthN/A Sales & Book Value Annual Sales$38.04 million Price / Sales21.79 Cash FlowN/A Price / Cash FlowN/A Book Value$1.45 per share Price / Book8.54 Profitability EPS (Most Recent Fiscal Year)($2.32) Net Income$-131,170,000.00 Net Margins-143.42% Return on Equity-71.94% Return on Assets-49.55% Miscellaneous Employees477 Outstanding Shares66,890,000Market Cap$899.05 million OptionableOptionable Athenex (NASDAQ:ATNX) Frequently Asked Questions What is Athenex's stock symbol? Athenex trades on the NASDAQ under the ticker symbol "ATNX." How were Athenex's earnings last quarter? Athenex Inc (NASDAQ:ATNX) issued its quarterly earnings results on Wednesday, November, 14th. The company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.12. The company had revenue of $18.43 million for the quarter. Athenex had a negative return on equity of 71.94% and a negative net margin of 143.42%. View Athenex's Earnings History. When is Athenex's next earnings date? Athenex is scheduled to release their next quarterly earnings announcement on Monday, March 25th 2019. View Earnings Estimates for Athenex. What guidance has Athenex issued on next quarter's earnings? Athenex issued an update on its FY 2018 earnings guidance on Wednesday, November, 14th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $100-100 million, compared to the consensus revenue estimate of $109.04 million. What price target have analysts set for ATNX? 4 brokerages have issued 12-month target prices for Athenex's shares. Their forecasts range from $15.00 to $30.00. On average, they anticipate Athenex's share price to reach $23.00 in the next year. This suggests a possible upside of 83.3% from the stock's current price. View Analyst Price Targets for Athenex. What is the consensus analysts' recommendation for Athenex? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athenex in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Athenex. Has Athenex been receiving favorable news coverage? Headlines about ATNX stock have been trending somewhat positive recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Athenex earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. Who are some of Athenex's key competitors? Some companies that are related to Athenex include Taro Pharmaceutical Industries (TARO), FibroGen (FGEN), Array Biopharma (ARRY), Horizon Pharma (HZNP), Emergent Biosolutions (EBS), Intercept Pharmaceuticals (ICPT), Agios Pharmaceuticals (AGIO), Ligand Pharmaceuticals (LGND), Evotec (EVTCY), Akcea Therapeutics (AKCA), Ascendis Pharma A/S (ASND), Allakos (ALLK), Blueprint Medicines (BPMC), Endo International (ENDP) and Ultragenyx Pharmaceutical (RARE). Who are Athenex's key executives? Athenex's management team includes the folowing people: Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D., Chairman & CEO (Age 58)Mr. Jeffrey M. Yordon, COO & Pres of Athenex Pharmaceutical Division (Age 69)Dr. Rudolf Kwan M.D., M.B., B.S., Exec. VP & Chief Medical Officer (Age 65)Mr. Kam-Chung Leung GBS, LLD, OBE, JP, Strategic & Bus. Advisor (Age 66)Mr. James H. Zukin, Strategic & Bus. Advisor to CEO (Age 69) When did Athenex IPO? (ATNX) raised $72 million in an initial public offering on Wednesday, June 14th 2017. The company issued 6,000,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan acted as the underwriters for the IPO and ICBC International was co-manager. Who are Athenex's major shareholders? Athenex's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.36%), Perceptive Advisors LLC (4.30%), Vanguard Group Inc. (2.81%), Vanguard Group Inc (2.81%), Hsbc Holdings PLC (1.59%) and Gilder Gagnon Howe & Co. LLC (0.33%). Company insiders that own Athenex stock include Jeffrey Yordon, Jinn Wu, Johnson Yiu Nam Lau, Manson Fok, Randoll Sze, Rudolf Kwan, Sheldon Trainor-Degirolamo and Song-Yi Zhang. View Institutional Ownership Trends for Athenex. Which institutional investors are selling Athenex stock? ATNX stock was sold by a variety of institutional investors in the last quarter, including Hsbc Holdings PLC, TIAA CREF Investment Management LLC, Virtus ETF Advisers LLC and Credit Suisse AG. Company insiders that have sold Athenex company stock in the last year include Sheldon Trainor-Degirolamo and Song-Yi Zhang. View Insider Buying and Selling for Athenex. Which institutional investors are buying Athenex stock? ATNX stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Northpointe Capital LLC, Vanguard Group Inc, Vanguard Group Inc., American Century Companies Inc., BlackRock Inc., Gilder Gagnon Howe & Co. LLC and Jaffetilchin Investment Partners LLC. Company insiders that have bought Athenex stock in the last two years include Jeffrey Yordon, Jinn Wu, Johnson Yiu Nam Lau, Manson Fok, Randoll Sze, Rudolf Kwan and Song-Yi Zhang. View Insider Buying and Selling for Athenex. How do I buy shares of Athenex? Shares of ATNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Athenex's stock price today? One share of ATNX stock can currently be purchased for approximately $12.55. How big of a company is Athenex? Athenex has a market capitalization of $899.05 million and generates $38.04 million in revenue each year. The company earns $-131,170,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis. Athenex employs 477 workers across the globe. What is Athenex's official website? The official website for Athenex is http://www.athenex.com. How can I contact Athenex? Athenex's mailing address is 1001 Main Street Suite 600, Buffalo NY, 14203. The company can be reached via phone at 716-427-2950. MarketBeat Community Rating for Athenex (NASDAQ ATNX)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 181 (Vote Outperform)Underperform Votes: 176 (Vote Underperform)Total Votes: 357MarketBeat's community ratings are surveys of what our community members think about Athenex and other stocks. Vote "Outperform" if you believe ATNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATNX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/14/2018 by MarketBeat.com StaffFeatured Article: What is an Initial Public Offering (IPO)?